An observational study in Bronchiolitis Acute, Lower Respiratory Tract and Lung Infections and Pediatric Lung Ultrasound, sponsored by Helse Møre og Romsdal HF. Recruiting at 2 sites in Norway. Open to participants aged 0 Days to 24 Months. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by Helse Møre og Romsdal HF · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Asthma with a site in Norway — 2 open to participants now, 3 under way, none of them phase 3. Asthma · Norway.
Among the 30 studies in Asthma with a site in Norway, this one is the only one that started in 2025, is one of 7 observational ones, and was the 30th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →2 of the 30 studies in Asthma with a site in Norway are open now. Recruiting first, the newest first:
St. Olavs Hospital · Sites in Norway, Finland, Sweden
Ages 3 mo–23 mo
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 0 Days to 24 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 318 across the 23 interventional studies, 200 across the 7 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 30 have an industry lead sponsor. The 10 most frequent:
Helse Møre og Romsdal HF is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Helse Møre og Romsdal HF has 1 study filed under Asthma — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Asthma with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lower respiratory tract infections (LRTIs) are a significant cause of childhood morbidity and mortality globally, particularly in low-income countries. In Norway, LRTIs is a leading cause of hospitalization among infants, representing a great socioeconomic burden.
Bronchiolitis, a viral infection, is the main representation of LRTIs in infants. It affects the small airways, causing breathing- and feeding difficulties. Today, treatment relies on subjective evaluations, lacking objective measures for assessment. This increases the risk of both under- and over treating patients. In the long term, bronchiolitis increases risk of asthma, but it is unknown who the high-risk patients for chronic lung disease are.
Lung ultrasonography (LUS) has emerged as a promising tool for assessing bronchiolitis severity and progression of the disease. The investigators will explore its use to improve diagnostic accuracy and treatment decisions, and develop AI-driven scoring tools for novel technology.
Additionally, tidal breathing flow volume loops (TBFVL) offer a non-invasive method for evaluating airway obstruction in infants, with the potential to assess severity of bronchiolitis, treatment efficacy and post-infection lung function.
In this project the investigators will combine the use of these modern technologies to improve treatment and follow-up of infants with LRTIs.
The main aim for this observational study is to assess the utility of lung ultrasonography (LUS) and tidal flow volume loops (TBFVL) in infant lower respiratory tract infections (LRTIs) for individual risk stratification in acute and chronic settings. This aims to refine the management of bronchiolitis, identifying high-risk patients for chronic lung disease to tailor treatment and follow-up protocols.
The project has three secondary objectives.
Lower respiratory tract infections (LRTIs) stand as the leading cause of hospitalization, while asthma is the leading cause of chronic lung disease among children in Nordic countries. The project seeks to improve risk stratification and treatment protocols in both acute and chronic settings.
In the acute setting, the project endeavors to prognosticate individual patient outcomes, thereby individualize treatment and mitigating unnecessary hospital admissions, use of respiratory support and antibiotic administration. Additionally there is potential of more aggressive treatment to selected patients. The study aims to improve the understanding of pathophysiological processes of LRTIs in infants, providing objective metrics to evaluate disease severity and individualize treatment.
The investigators aim to validate the utility, validity, and simplicity of handheld ultrasound devices as bedside diagnostic tools for this common disease, alongside affirming the value of tidal flow volume loops (TBFVL) in acute and chronic settings to assess airway obstruction in infants. Combining these modern technologies, evaluating affliction of both the parenchyme and the airways will probide a new perspective in treatment of LRTIs. In addition the project will strive to develop novel technology with AI-driven scoring tools of LUS.
Furthermore, the project aims to examine the trajectory of symptoms post-LRTI and facilitate the early identification of patients with high-risk of chronic lung disease. Early detection of asthma and other chronic lung diseases holds the potential to improve outcomes and mitigate the need for hospitalization, thus easing both economic and emotional burdens associated with the disease.
For caregivers, the lack of information concerning symptom duration and risk of future disease represents a significant knowledge gap. The project aims to address this, by examining post-infection symptom duration and identifying high-risk cohorts predisposed to chronic lung disease. This has the potential to both improve information, personalize follow-up and reduce hospital readmissions.
children under 2 years of age, hospitalized with lower respiratory tract infections. single cohort study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: lung ultrasound · Diagnostic Test: Tidal-flow volume loops
performance of lung utltrasound in participants, performed bedside (v scan).
tidal-flow volume loops performed in patients hospitalized with lower respiratory tract infections.
Number of readmissions at 1 year follow-up after baseline.
All participants will be followed for 1 year after first hospitalization with LRTI. At that point investigators will retrieve data on readmissions as primary outcome, correlated with initial findings.
Time frame: From enrollment to the end of follow-up at 12 months.
Length of stay at hospital due to LRTI.
Primay outcome is length of stay at hospital, correlated with findings at hospitalization (lung ultrasound and tidal-flow volume loops)
Time frame: from enrollment to discharge from hospital, average patient is hospitalized 3 days.
Duration of symptoms after hospitalization due to LRTI.
duration of symptoms after hospitalization with lower respiratory tract infection, marked by symptom diary and follow-up by phone call. Participants are deemed free of symptoms when they are in habitual state without cough.
Time frame: from enrollment to weeks/months after discharge, based on reporting of symptoms. Up to 60 days.
Use of respiratory support correlated with lung ultrasound score and tidal-flow volume loop results
secondary outcome is degree of respiratory support correlated with findings on lung ultrasound (LUS) and tidal-flow volume loops (TBFVL). Investigators will monitor the use of NIV (HFNC, C-PAP, mechanical ventilation) in enrolled participants and correlate with results from TBFVL and scoring from LUS.
Time frame: form enrollment to discharge from hospital, average hospitalization is 3 days.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Jun 2029, 42 months after the start.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 42 months is above that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Møre og Romsdal HF